HomeNewscoronavirusOmicron reportedly has 30+ mutations in spike protein region, may bypass vaccines: AIIMS chief

Omicron reportedly has 30+ mutations in spike protein region, may bypass vaccines: AIIMS chief

The Indian SARS-CoV-2 Genomic Consortia INSACOG is closely tracking the new variant of COVID-19 called B.1.1.529 and its presence has not been detected yet in the country, officials have said.

November 28, 2021 / 16:23 IST
Story continues below Advertisement
AIIMS Director Dr Randeep Guleria (Image Source: ANI)
AIIMS Director Dr Randeep Guleria (Image Source: ANI)

The new Omicron variant of coronavirus has reportedly got over 30 mutations in the spike protein region giving it the potential to develop an immune escape mechanism, and thus the efficacy of vaccines against it needs to be evaluated critically, AIIMS chief Dr Randeep Guelria has said. .

The presence of spike protein facilitates a virus' entry into the host cell and is responsible for making it transmissible and causing infection.

Story continues below Advertisement

"The new variant of coronavirus reportedly has got more than 30 mutations at the spike protein region and therefore has the potential of developing immunoescape mechanisms. As most vaccines (work by) forming antibodies against the spike protein, so many mutations at the spike protein region may lead to a decreased efficacy of COVID-19 vaccines," AIIMS Director Dr Randeep Guelria told PTI.

In such a scenario, the efficacy of vaccines including those in use in India needs to be evaluated "critically", he said. The future course of action will depend on what more data on its transmissibility, virulence and immunoescpae shows, he said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show